Zobrazeno 101 - 110
of 157
pro vyhledávání: '"Odd Erik Johansen"'
Publikováno v:
Heart Failure Reviews. 23:819-819
Autor:
Arnljot Tveit, Odd Erik Johansen
Publikováno v:
AME Medical Journal. 2:178-178
There is a steady increase in the global prevalence of atrial fibrillation (AF) in all regions of the world (1,2) and in the European Union an increase from 8.8 million adults over 55 years in 2010, to 17.9 million in 2060, is estimated (3). Part of
Heart rate adjustments and analysis of recovery patterns of ST-segment depression in type 2 diabetes
Autor:
Karl G. Blaasaas, Kåre I. Birkeland, Lars Gullestad, Odd Erik Johansen, Svend Aakhus, Knut Endresen, Thorvald Bjurö
Publikováno v:
International Journal of Cardiology. 127:129-132
Aims To investigate the diagnostic value for coronary artery disease (CAD) detection of evaluating time- and heart rate (HR)-related ST-segment changes (the ST/HR-slope) and the post-exercise recovery pattern (the ST/HR-recovery loop) in patients wit
Autor:
Ragnhild Wergeland, Ø. Flesland, P. Aukrust, Lars Gullestad, Elsa Orvik, Odd Erik Johansen, Knut Endresen, Kåre I. Birkeland, Camilla Smith, Thor Ueland
Publikováno v:
Scandinavian Journal of Clinical and Laboratory Investigation. 67:306-316
Coronary artery disease (CAD) is prevalent in patients with type 2 diabetes mellitus (T2DM) and because it is often asymptomatic and extensive in comparison with CAD in subjects without diabetes, it represents a diagnostic challenge. The objective of
Autor:
Sanjay Patel, Julio Rosenstock, Nikolaus Marx, Thomas Seck, Dietmar Neubacher, Odd Erik Johansen, Hans-Juergen Woerle
Publikováno v:
Cardiovascular Diabetology
Cardiovascular diabetology 14(1), 57 (2015). doi:10.1186/s12933-015-0215-2
Cardiovascular diabetology 14(1), 57 (2015). doi:10.1186/s12933-015-0215-2
Cardiovascular diabetology 14(1), 57 (2015). doi:10.1186/s12933-015-0215-2
Published by BioMed Central, London
Published by BioMed Central, London
Autor:
Dietmar Neubacher, Bernard Zinman, Sanjay Patel, Odd Erik Johansen, Hans-Juergen Woerle, Bo Ahrén
Publikováno v:
Canadian journal of diabetes. 40(1)
With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl pepti
Autor:
Odd Erik Johansen
Publikováno v:
World journal of diabetes. 6(9)
In cardiovascular (CV) diabetology a "one-size fits-all" approach needs caution as vasculopathy and CV manifestations in patients with type 2 diabetes (T2D) with short disease duration are different as compared to those with longer duration. This is
Autor:
Bernard Zinman, David Fitchett, Rosa-Maria Espadero, Stefan Hantel, Uli C. Broedl, Christoph Wanner, Hans-Juergen Woerle, Roberto Ferrari, Odd Erik Johansen, Silvio E. Inzucchi
Publikováno v:
Diabetes & Vascular Disease Research
Given the multi-faceted pathogenesis of atherosclerosis in type 2 diabetes mellitus (T2DM), it is likely that interventions to mitigate this risk must address cardiovascular (CV) risk factors beyond glucose itself. Sodium glucose cotransporter-2 (SGL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ecac04a5502be8656d68101e1655f9
http://hdl.handle.net/11392/2343805
http://hdl.handle.net/11392/2343805
Autor:
Roger Mazze, Bruce A. Perkins, Nima Soleymanlou, Justin A. Lee, David Z.I. Cherney, Holly Tschirhart, Stefan Kaspers, Nora M. Fagan, Uli C. Broedl, Odd Erik Johansen, Hans-Juergen Woerle, Helen Partridge, Bernard Zinman
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0141085 (2015)
PLoS ONE
PLoS ONE
Background We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal gl
Autor:
John M. Lachin, Bernard Zinman, Steven E. Kahn, Hans-Juergen Woerle, Julio Rosenstock, Sanjay Patel, Bart Ryckaert, Mark A. Espeland, Odd Erik Johansen, Erich Bluhmki, John J. Kastelein, Nikolaus Marx, Michaela Mattheus
Publikováno v:
Diabetes & vascular disease research, 12(3), 164-174. SAGE Publications Ltd
Diabetes & Vascular Disease Research
Diabetes & Vascular Disease Research
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52cd5712f01d07cb467794c9e5e05163
https://pure.amc.nl/en/publications/design-and-baseline-characteristics-of-the-cardiovascular-outcome-trial-of-linagliptin-versus-glimepiride-in-type-2-diabetes-carolina-r(6a935be8-a261-4dbd-98b4-2b7b30b77aed).html
https://pure.amc.nl/en/publications/design-and-baseline-characteristics-of-the-cardiovascular-outcome-trial-of-linagliptin-versus-glimepiride-in-type-2-diabetes-carolina-r(6a935be8-a261-4dbd-98b4-2b7b30b77aed).html